FierceBiotech1d
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
emjreviews.com2d
New Model Predicts Hepatocellular Carcinoma Risk in Patients with Noncirrhotic Hepatitis B
New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.
The Lancet3d
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B
Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...
The American Journal of Managed Care5d
New AGA Guidelines Recommend Risk-Based Prophylaxis for Hepatitis B Reactivation Monitoring
The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...
Healio6d
Viral hepatitis elimination requires equitable public health approach
Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...
emjreviews.com6d
Vaccine Shows Promise for Chronic Hepatitis B Treatment
Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.
clinicaladvisor.com6d
Brelovitug Granted Breakthrough Designation for Chronic Hepatitis Delta
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).